Scientific article
English

Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants

Published in

Journal of thrombosis and haemostasis, vol. 6, no. 2, p. 227-229

Publication date

2008

Keywords

  • Anticoagulants/standards/therapeutic use
  • Bias (Epidemiology)
  • Case Management
  • Clinical Trials, Phase III as Topic/methods/standards
  • Cost-Benefit Analysis
  • Double-Blind Method
  • Fibrinolytic Agents/standards/therapeutic use
  • Heparin/therapeutic use
  • Heparin, Low-Molecular-Weight/therapeutic use
  • Humans
  • Patient Selection
  • Professional Practice
  • Prothrombin Time/instrumentation
  • Quality of Life
  • Randomized Controlled Trials as Topic/methods/standards
  • Thrombophilia/drug therapy
  • Treatment Outcome
  • Vitamin K/antagonists & inhibitors

Citation (ISO format)

BULLER, Harry R. et al. Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants. In: Journal of thrombosis and haemostasis, 2008, vol. 6, n° 2, p. 227–229. doi: 10.1111/j.1538-7836.2007.02848.x

Main files (1)

Article (Accepted version)

Identifiers

Journal ISSN

1538-7836
651views
0downloads

Technical informations

Creation

02/06/2009 08:39:00

First validation

02/06/2009 08:39:00

Update

09/02/2026 14:34:42

Status update

09/02/2026 14:34:42

Last indexation

20/04/2026 15:26:24
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated